About Autolus Therapeutics plc
https://www.autolus.comAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer.
CEO
Christian Martin Itin
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
MAK CAPITAL ONE LLC
Shares:26.02M
Value:$36.95M
BLACKSTONE INC.
Shares:20.49M
Value:$29.09M
SYNCONA PORTFOLIO LTD
Shares:16.64M
Value:$23.63M
Summary
Showing Top 3 of 108
About Autolus Therapeutics plc
https://www.autolus.comAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $21.19M ▲ | $64.17M ▲ | $-79.12M ▼ | -373.3% ▼ | $-0.3 ▼ | $-64.7M ▼ |
| Q2-2025 | $20.92M ▲ | $57.7M ▲ | $-47.92M ▲ | -229.02% ▲ | $-0.18 ▲ | $-56.91M ▼ |
| Q1-2025 | $8.98M ▲ | $56.27M ▼ | $-70.16M ▼ | -781.13% ▲ | $-0.26 ▼ | $-55.52M ▲ |
| Q4-2024 | $29K ▲ | $103.15M ▲ | $-27.61M ▲ | -95.19K% ▼ | $-0.1 ▲ | $-73.79M ▼ |
| Q3-2024 | $0 | $67.65M | $-82.09M | 0% | $-0.31 | $-65.72M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $367.41M ▼ | $661.95M ▼ | $396.5M ▲ | $265.45M ▼ |
| Q2-2025 | $454.28M ▼ | $720.98M ▼ | $374.52M ▼ | $346.46M ▼ |
| Q1-2025 | $516.58M ▼ | $746.34M ▼ | $375.23M ▲ | $371.11M ▼ |
| Q4-2024 | $588.02M ▼ | $782.73M ▼ | $355.4M ▲ | $427.32M ▼ |
| Q3-2024 | $657.07M | $827.49M | $350.52M | $476.96M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-79.11M ▼ | $-67.9M ▲ | $35.55M ▼ | $-1.77M ▼ | $-37.71M ▼ | $-52.38M ▲ |
| Q2-2025 | $-47.92M ▲ | $-72.78M ▲ | $95.92M ▲ | $-768K ▼ | $28.08M ▲ | $-80.06M ▲ |
| Q1-2025 | $-70.16M ▼ | $-75.56M ▼ | $-59.55M ▲ | $0 ▼ | $-131.55M ▲ | $-83.81M ▼ |
| Q4-2024 | $-27.61M ▲ | $-37.93M ▲ | $-383.59M ▼ | $30.01M ▲ | $-429.73M ▼ | $-61.79M ▲ |
| Q3-2024 | $-82.09M | $-76.74M | $-9.59M | $185K | $-48.42M | $-86.33M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $0 ▲ | $10.00M ▲ | $20.00M ▲ | $20.00M ▲ |
Revenue by Geography
| Region | Q1-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Europe | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $10.00M ▲ | $20.00M ▲ | $0 ▼ |
 GERMANY | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Christian Martin Itin
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
MAK CAPITAL ONE LLC
Shares:26.02M
Value:$36.95M
BLACKSTONE INC.
Shares:20.49M
Value:$29.09M
SYNCONA PORTFOLIO LTD
Shares:16.64M
Value:$23.63M
Summary
Showing Top 3 of 108